Supporting Information

Rapidly Modular Synthesis of Indole Ethers via Dehydrogenative Cross-Coupling Reaction of Indoles and Alcohols

Mao-Gui Huang,[†] Xiao-Hong Chen,[†] Hai-Bing Xu[†], Yue-Jin Liu*[†]

[†]Collaborative Innovation Center for Advanced Organic Chemical Materials Co-constructed by the Province and Ministry, Ministry of Education Key Laboratory for the Synthesis and Application of Organic Functional Molecules. College of Chemistry and Chemical Engineering, Hubei University, Wuhan, 430062, China.

*liuyuejin@hubu.edu.cn.

Contents

1. General Information
2. Experimental Procedures
2.1 Preparation of indole-3-carboxamides substrates
2.2 General procedures for substrate 3m, 3n, 3o, 4m, 4o, 4q, 4r, 6S4
2.3 Optimization of Conditions
2.4 General procedures for Co-catalyzed alkoxylation of indolyl amides with primary alcohol
2.5 General procedure for large-scale reaction
2.6 General procedure for futher diversification of product 5a
2.7 General procedure for futher diversification of product 5bS10
2.8 General procedure for futher diversification of product 5cS10
2.9 Synthesis of 5-HT4-receptor antagonist analogueS11
2.10 General procedure for synthesis of Co catalyst
2.11 Mechanism investigations
3. Characterization Data
4. References
5. Crystallographic Data
6. NMR Spectra

1. General Information

Solvents: Dichloromethane was distilled from CaH₂ and other solvents used in this manuscript were purchased from commercial suppliers.

Reagents: All commercial materials, purchased from Alfa-Aesar, Macklin, Adamas, Bidepharm and Aladdin and used as received.

Reactions: All sample preparation reactions were performed in oven-dried glassware under an atmosphere of oxygen unless.

Chromatography: Thin layer chromatography (TLC) was carried out on silica gel 60 F254 pre-coated glass plates. Visualization was detected by irradiation with UV light (254 nm), or by treatment with a solution of phosphomolybdic acid in ethanol followed by heating. Flash chromatography was carried out on 200 - 300 mesh silica gel, eluting with a mixture of petroleum ether (b.p. 60 - 90 °C), ethyl acetate and dichloromethane.

NMR Spectroscope: ¹H NMR and ¹³C NMR and ¹⁹F NMR spectra were recorded on a Bruker Mercury Plus 400 MHz NMR spectrometers. Chemical shifts (δ) were given in parts per million (ppm), and referenced relative to residual solvent CHCl₃ (7.26 ppm) in CDCl₃, or tetramethylsilane (0.00 ppm) as an internal standard for ¹H NMR spectra and deuterated solvent CDCl₃ (77.16 ppm) for ¹³C NMR spectra. Coupling constants (*J*) were reported in hertz (Hz). The following abbreviations are used to indicate the multiplicity of the signals: s = singlet, d = doublet, t = triplet, m = multiplet, and associated combinations, e.g. dd = doublet of doublets.

Mass Spectrometry: High resolution mass spectra (HRMS) were recorded on the Thermo Scientific Exactive Plus (orbitrap) equipped with ESI ionization source.

Crystallography: Single crystals of 3aa suitable for X-ray diffraction were grown by layering hexane on the dichloromethane solutions and Co-2 suitable for X-ray diffraction were grown by layering MeCN on the DMF solutions. The diffraction data of crystals were collected on a Rigaku XtaLAB Synergy CCDC diffractometer with graphite monochromated Cu-Ka radiation ($\lambda = 1.54056$ Å) at 293 or 100 K. Absorption corrections were applied by SADABS. The ellipsoid contour is 50% probability in the caption for the image of the 3aa and Co-2. All the structures were solved by direct methods and refined by full-matrix least-squares method on F2 using Olex-2. All non-hydrogen atoms were refined with anisotropic displacement parameters. The hydrogen atoms of the ligand were generated geometrically.

2. Experimental Procedures



2.1 Preparation of indole-3-carboxamides substrates

Methylation of indoles were done according to the literature procedure¹.

To a solution of indole **A** (10 mmol) in anhydrous THF (30 mL) at 0 °C was added NaH (0.60 g, 60 % dispersion in mineral oil, 15 mmol). the heterogeneous mixture was stirred at 0 °C for 15 minutes and 1 h at room temperature. The mixture was then cooled to 0 °C, treated with iodomethane (14 mmol), and allow to warm to room temperature. After 3 hour, the reaction mixture was cooled to 0 °C, quenched with saturated NH₄Cl (40 mL), and extracted with ether (3 x 50 mL). The organic layers were combined, washed with brine, dried over anhydrous Na₂SO₄, and concentrated in vacuo. The resulting oil was purified by flash chromatography (eluent: petroleum ether/EtOAc 10:1) to provide indole **B** as a colorless oil.

Typical procedure for synthesis of trifluoromethyl indol-3-yl ketones indoles **C**. Indole **B** (0.2 mmol) and trifluoroacetic anhydride (3 equiv) were refluxed in a 100 °C oil bath in 2 mL of DCE in an air atmosphere, and the progress of the reaction was monitored by TLC. After completion of the reaction, as determined by TLC, the reaction mixture was cooled to room temperature. Water (2 x 5 mL) was added, the product was extracted with ethyl acetate (20 mL), the organic layers were washed with saturated brine, and the solvent was removed on a rotary evaporator. The product was purified by silica gel chromatography (petroleum ether/EtOAc 5/1) to afford the corresponding products C.

A 100 mL round bottom flask was charged with 2,2,2-trifluoro-1-(1-methylindol-3-yl)ethan-1-one C (1.135 g, 5.0 mmol), NaOH (5 M,

30.0 mL), methanol (10 mL), and a magnetic stirring bar. The reaction mixture was refluxed for 12 h and then cooled to room temperature, and H₂O (10 mL) was added. The layers were separated, and the organic layer was extracted with 1 M aqueous NaOH (10 mL). The combined aqueous phases were acidified to PH = 1 with 12 M aqueous HCl, then the solution has been turned into suspension. the solid were filtered from this suspension. The solid was dried to afford the corresponding product **D**.

Procedures were done according to the literature procedure².

To an oven-dried 100 mL bottom flask, the benzoic acid **D** (20 mmol), DMF (5 drops) and anhydrous DCM (40 mL) were added under a Ar atmosphere. Oxalyl chloride (2 mL, 24 mmol, 1.2 equiv.) was added dropwise at 0 °C resulting in vigorous bubbling. The mixture was stirred for 5 h at room temperature, and the solvent was then removed in vacuo. The resulting acid chloride **E** was used immediately without further purification.

To another oven-dried 100 mL three-necked flask, 8-aminoquinoline (3.75 g, 26 mmol, 1.3 equiv.), Et₃N (5.6 mL, 40 mmol, 2 equiv.) and anhydrous DCM (40 mL) were added. A solution of the acid chloride **E** in anhydrous DCM (20 mL) was added dropwise to the solution at 0 °C, and the solution was then warmed to room temperature. After stirring overnight, the reaction system was quenched with sat. aq. NaHCO₃ (30 mL) and the organic layer was separated. The aqueous layer was extracted with DCM (2 x 20 mL). The combined organic layers were washed with 1 M HCl aq. (40 mL) and brine (30 mL), dried over MgSO₄, filtered and evaporated in vacuo. The obtained crude amide was purified by column chromatography on silica gel (petroleum ether/DCM/EtOAc 2/1/1) to afford the desired amide **F**.



2.2 General procedures for substrate 3m, 3n, 3o, 4m, 4o, 4q, 4r, 6.

Procedures G to I were done according to the literature procedure²

To an oven-dried 100 mL bottom flask, the 1H-indole-3-carboxylic acid **G** (20 mmol), DMF (5 drops) and anhydrous DCM (40 mL) were added under a Ar atmosphere. Oxalyl chloride (2 mL, 24 mmol, 1.2 equiv.) was added dropwise at 0 °C resulting in vigorous bubbling. The mixture was stirred for 5 h at room temperature, and the solvent was then removed in vacuo. The resulting acid chloride **H** was used immediately without further purification.

To another oven-dried 100 mL three-necked flask, 8-aminoquinoline (3.75 g, 26 mmol, 1.3 equiv.), Et₃N (5.6 mL, 40 mmol, 2 equiv.) and anhydrous DCM (40 mL) were added. A solution of the acid chloride **H** in anhydrous DCM (20 mL) was added dropwise to the solution at 0 °C, and the solution was then warmed to room temperature. After stirring overnight, the reaction system was quenched with sat. aq. NaHCO₃ (30 mL) and the organic layer was separated. The aqueous layer was extracted with DCM (2 x 20 mL). The combined organic layers were washed with 1 M HCl aq. (40 mL) and brine (30 mL), dried over MgSO₄, filtered and evaporated in vacuo. The obtained crude amide was purified by column chromatography on silica gel (petroleum ether/DCM/EtOAc 2/1/1) to afford the desired amide **I**.

Procedures I to J were done according to the literature procedure².

To a solution of indole **I** (10 mmol) in anhydrous DCM (30 mL) at 0 °C was added NaH (0.60 g, 60 % dispersion in mineral oil, 15 mmol). the heterogeneous mixture was stirred at 0 °C for 15 minutes and 1 h at room temperature. The mixture was then cooled to 0 °C, treated with alkyl -Br or alkyl -I (14 mmol), and allow to warm to room temperature. After 3 hour, the reaction mixture was cooled to 0 °C, quenched with saturated NH₄Cl (40 mL), and extracted with ether (3 x 50 mL). The organic layers were combined, washed with brine, dried over anhydrous Na₂SO₄, and concentrated in vacuo. The resulting crude amide was purified by flash chromatography (eluent: petroleum ether/EtOAc 3:1) to provide indole **J** as a solid product.

2.3 Optimization of Conditions



Entry	Catalyst	Oxidant	Base	Solvent	Yield 3aa:3a'[%] ^a
1	Co-2	Ag ₂ O	KH ₂ PO ₄	2-MeTHF	28 % : < 5 %
2	Co-2	Ag ₂ O	KH ₂ PO ₄	MeCN	16 % : < 5 %
3	Co-2	Ag ₂ O	KH ₂ PO ₄	Dioxane	20 % : 20 %
4	Co-2	Ag ₂ O	KH ₂ PO ₄	THF	25 % : < 5 %
5	Co-2	Ag ₂ O	KH ₂ PO ₄	Phe-OMe	33 % : 10 %
6	Co-2	Ag ₂ O	KH ₂ PO ₄	EA	60 % : 0 %
7	Co-2	Ag ₂ O	KH ₂ PO ₄	DCE	55 % : < 5 %
8	Co-2	Ag ₂ O	K ₃ PO ₄	EA	22 % : 8 %
9	Co-2	Ag ₂ O	K ₂ CO ₃	EA	10 % : 16 %
10	Co-2	Ag ₂ O	KOAc	EA	40 % : < 5 %
11	Co-2	Ag ₂ O	CF3COOK	EA	60 % : < 5 %
12	Co-2	Ag ₂ O	KHCO ₃	EA	56 % : < 5 %
13	Co-2	Ag ₂ O	K ₂ HPO ₄	EA	29 % : < 5 %
14	Co-2	Ag ₂ O	CsCO ₃	EA	0 % : 30 %
15	Co-2	Ag ₂ O	KHSO4	EA	45 % : < 5 %
16	Со-2	Ag ₂ O		EA	85 % : < 5 %
17	Co-2	Ag ₂ CO ₃		EA	76 % : 0 %
18	Co-2	Mn(OAc) ₂		EA	0 % : < 5 %
19	Co-2	MnO ₂		EA	0 % : < 5 %
20	Co-2	Mn(OAc)3		EA	20 % : < 5 %
21	Co-1	Ag ₂ O		EA	53 % : < 5 %

22	Co-3	Ag ₂ O	 EA	79 % : < 5 %
23	Co-4	Ag ₂ O	 EA	56 % : < 5 %
24	Co-5	Ag ₂ O	 EA	66 % : < 5 %
25	Co-6	Ag ₂ O	 EA	70 % : < 5 %
26	Co-7	Ag ₂ O	 EA	68 % : < 5 %
27	Co-8	Ag ₂ O	 EA	72 % : < 5 %
28	Co-9	Ag ₂ O	 EA	73 % : < 5 %
29	Co-10	Ag ₂ O	 EA	15 % : 8 %
30	Co-11	Ag ₂ O	 EA	17 % : 10 %
31	Co(NO ₂)3 [.] 6H ₂ O	Ag ₂ O	 EA	0 % : 0 %
32	Pd(OAc) ₂ (10 mol%)	Ag ₂ O	 EA	0 % : 0 %
33	[RuCl ₂ (<i>p</i> -cymene)] ₂ (5 mol%)	Ag ₂ O	 EA	0 % : 0 %
34	Co(acac) ₂	Ag ₂ O	 EA	55 % : < 5 %
35	Co(OAc) ₂	Ag ₂ O	 EA	< 5 % : < 5 %
36	Cu(acac) ₂	Ag ₂ O	 EA	< 5 % : < 5 %
37	Cu(OAc) ₂ (20 mol%)	Ag ₂ O	 EA	40 % : < 5 %
38	Cp*Co(CO)I2	Ag ₂ O	 EA	51 % : < 5 %

^{*a*} Reaction conditions: **1a** (0.1 mmol), **2a** (10 equiv), Catalyst (20 mol%), base (2 equiv), oxidant (2 equiv) and EA (1 mL), at 100 °C for 12 h under air. Yield were determined by ¹H NMR analysis and CH₂Br₂ were added as an inner standard.



2.4 General procedures for Co-catalyzed alkoxylation of indolyl amides with primary alcohol



In a 25 mL sealed tube, 1 mL EA was added to a mixture of **1** (0.1 mmol, 1.0 equiv.), Co-2 (7.7 mg, 20 mol%), Ag₂O (46.3 mg, 2.0 equiv.), alcohol **2** (5-10 equiv) under air. The tube was sealed with a Teflon lined cap and the reaction mixture was stirred at 100 °C by heating metal mantle for 12 h. After cooling to room temperature, the mixture was filtered over celite, concentrated under vacuum and the residue was purified by preparative chromatography with a gradient eluent of petroleum ether, ethyl acetate and dichloromethane to give the corresponding products.

2.5 General procedure for large-scale reaction



In a 150 mL sealed tube, 30 mL EA was added to a mixture of 1-methyl-N-(quinolin-6-yl)-1H-indole-3-carboxamide **1a** (3.5 mmol, 1.0 equiv.), Co-2 (270 mg, 20 mol%), Ag₂O (1617 mg, 2.0 equiv.), CH₃OH **2a** (10 equiv.) under

air. The tube was sealed with a Teflon lined cap and the reaction mixture was stirred at 100 °C in oil bath for 12 h. After cooling to room temperature, the mixture was filtered over celite, concentrated under vacuum and the crude product was purified by column chromatography on silica gel ($R_f = 0.5$, petroleum ether/DCM/EtOAc 4/1/1) affording the pure product **3aa** (yellow solid, 0.9 g, 78% yield).

2.6 General procedure for futher diversification of product 5a



Procedures were done according to the literature procedure³.

Step 1: To an ice-water cooled solution of compound 2-methoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3aa, 33 mg, 0.1 mmol, 1 equiv) and DMAP (3 equiv) in anhydrous CH_2Cl_2 (1 mL) was added Boc₂O (5 equiv). The reaction mixture was stirred at 60 °C for 12 h. The reaction mixture was concentrated in vacuo, and the resulting residue was purified by silica gel flash chromatography.

Step 2: To a solution of N-Boc-protected amide (0.1 mmol) in t-BuOMe:MeOH (3:1, 1 mL) was added NaOMe (3equiv) in one portion. The resulting mixture was stirred at room temperature for 4 h. The reaction was quenched with a saturated aqueous NH₄Cl solution, extracted with EtOAc (30 mL × 3). The combined organic layers were washed with water and brine. The organic layer was separated, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel to afford the desired methyl ester **5a** (13 mg, 61%). ¹H NMR (400 MHz, CDCl₃) δ 8.08 – 8.03 (m, 1H), 7.24 (dd, *J* = 6.0, 4.0 Hz, 3H), 4.23 (s, 3H), 3.93 (s, 3H), 3.63 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 164.9, 131.7, 125.2, 122.2, 122.1, 121.4, 109.1, 90.8, 63.4, 51.0, 27.9. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₁₂H₁₄NO₃⁺): 220.0968, found: 220.0964.

2.7 General procedure for futher diversification of product 5b



Procedures were done according to the literature procedure⁴.

A solution of 2-methoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3aa, 33 mg, 0.1 mmol, 1 equiv) and NaOH (40 mg, 10 equiv) in ethanol (1 mL) was heated at 100 °C for 12 h. After this period, the reaction mixture was diluted with water and extracted with ether (2 × 10 mL). The aqueous layer was acidified with 1 N HCl and extracted with ether(2 × 10 mL). The combined organic layers were dried over Na₂SO₄, and then the solvent was evaporated in vacuo. The residue was purified by flash column chromatography on silica gel to afford the product **5b** (24 mg, 77%). ¹H NMR (400 MHz, CDCl₃) δ 11.58 (s, 1H), 8.98 (dd, *J* = 4.4, 1.6 Hz, 1H), 8.79 (dd, *J* = 6.14, 2.8 Hz, 1H), 8.16 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.82 (d, *J* = 7.6 Hz, 1H), 7.55 – 7.51 (m, 2H), 7.47 (dd, *J* = 8.4, 4.6 Hz, 1H), 7.41 – 737 (m, 1H), 7.23 – 719 (m, 1H), 6.91 (d, *J* = 8.0 Hz, 1H), 4.64 (s, 1H), 3.33 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 172.9, 162.6, 149.0, 143.9, 139.3, 136.3, 134.6, 129.0, 128.2, 127.3, 127.1, 123.34, 122.3, 121.8, 117.2, 108.5, 52.1, 26.9. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₁₉H₁₆N₃O₂⁺): 318.1237, found: 318.1234.

2.8 General procedure for futher diversification of product 5c



Procedures were done according to the literature procedure⁵.

To a solution of 2-methoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carbox -amide 3aa (33 mg, 0.1 mmol, 1 equiv) in dry methanol (1 mL) was added BF₃·Et₂O (0.1 mL, 6 equiv) dropwise. Then the resulting mixture was stirred at 100°C for 12 h and allowed to attain rt. Et₃N (1 mL) was added dropwise to the reaction mixture with stirring, and then the solvent was evaporated in vacuo. The residue was purified by flash column chromatography on silica gel to afford the product **5c** (13 mg, 86%).¹H NMR (400 MHz, CDCl₃) δ 7.30 (d, J = 7.6 Hz, 1H), 7.25 (d, J = 7.6 Hz, 1H), 7.07 – 7.02 (m, 1H), 6.82 (d, J = 7.6 Hz, 1H), 3.53 (s, 2H), 3.22 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 175.3, 145.4, 128.0, 124.6, 124.5, 122.5, 108.2, 35.9, 26.3. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₉H₁₀N₃O⁺): 148.0757, found: 148.0754.

2.9 Synthesis of 5-HT4-receptor antagonist analogue



In a 25 mL sealed tube, 1 mL DCE was added to a mixture of 1-(3-hydroxypropyl)-N-(quinolin-8-yl)-1H-indole-3-carboxamide **1** (0.1 mmol, 1.0 equiv.), Co-2 (7.7 mg, 20 mol%), Ag₂O (46.3 mg, 2.0 equiv.) under air. The tube was sealed with a Teflon lined cap and the reaction mixture was stirred at 100 °C by heating metal mantle for 12 h. After cooling to room temperature, the mixture was filtered over celite, concentrated under vacuum and the residue was purified by preparative chromatography with a gradient eluent of petroleum ether, ethyl acetate and dichloromethane to give the corresponding products **8** (**41** %). ¹H NMR (400 MHz, CDCl₃) δ 10.60 (s, 1H), 8.96 (d, *J* = 7.6 Hz, 1H), 8.70 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.32 (dd, *J* = 8.0, 1.2 Hz, 1H), 8.18 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.59 – 7.55 (m, 1H), 7.50 (d, *J* = 8.2 Hz, 1H), 7.45 (dd, *J* = 8.2, 4.0 Hz, 1H), 7.29 (dd, *J* = 10.0, 4.4 Hz, 3H), 4.70 – 4.62 (m, 2H), 4.53 – 4.49 (m, 2H), 2.57 – 2.50 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 163.3, 150.3, 148.0, 139.0, 136.4, 136.4, 131.6, 127.9, 126.0, 122.5, 121.3, 121.1, 121.1, 120.2, 116.4, 107.9, 90.5, 67.1, 39.2, 21.4. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₁H₁₈N₃O⁺): 344.1394, found: 344.1391.

2.10 General procedure for synthesis of Co catalyst



Procedures were done according to the literature procedure⁶.

The metal acetate of Co (6.0 mmol) was dissolved in ethanol (10 mL) in a 100 mL

round-bottomed fask, and it added the solution of salicylaldehyde (2.94 g, 24.0 mmol) in ethanol (40 mL). The solution was stirred at 80 °C in an oil bath for 24 h. Cobalt formed a yellow precipitate. The precipitate was fltered and washed with DCM. The residue was dried at 100 °C in an air oven for 24 h to get a pure **Co catalyst**.

2.11 Mechanism investigations



In a 25 mL sealed tube, 1 mL EA was added to a mixture of 1-methyl-N-(quinolin-6-yl)-1H-indole-3-carboxamide **1a** (0.1 mmol, 1.0 equiv.), Co-2 (7.7 mg, 20 mol%), Ag₂O (46.3 mg, 2.0 equiv.), CH₃OH (10 equiv) under air. The tube was sealed with a Teflon lined cap and the reaction mixture was stirred at 100 °C by heating metal mantle for 12 h. After cooling to room temperature, the mixture was filtered over celite, concentrated under vacuum and the residue was subject to ¹H NMR test to determine the yield of **3aa**. Yield were determined by ¹H NMR analysis and CH₂Br₂ were added as an inner standard.



In a 25 mL sealed tube, 1 mL EA was added to a mixture of 1-methyl-N-(quinolin-6-yl)-1H-indole-3-carboxamide **1a** (0.1 mmol, 1.0 equiv.), Co-2 (7.7 mg, 20 mol%), Ag₂O (46.3 mg, 2.0 equiv.), CD₃OD (10 equiv) under air. The tube was sealed with a Teflon lined cap and the reaction mixture was stirred at 100 °C by heating metal mantle for 12 h. After cooling to room temperature, the mixture was filtered over celite, concentrated under vacuum and the residue was subject to ¹H NMR test to determine the ratio of **3ap**. Yield were determined by ¹H NMR analysis and CH₂Br₂ were added as an inner standard.



Figure S2. ¹H NMR spectrum of the mixture system of 3ap



In a 25 mL sealed tube, 1 mL EA was added to a mixture of 1-methyl-N-(quinolin-6-yl)-1H-indole-3-carboxamide **1a** (0.1 mmol, 1.0 equiv.), Co-1 (7.7 mg, 20 mol%), Ag₂O (46.3 mg, 2.0 equiv.), CD₃COOD (20 equiv) under air. The tube was sealed with a Teflon lined cap and the reaction mixture was stirred at 100 °C by heating metal mantle for 12 h. After cooling to room temperature, the mixture was filtered over celite, concentrated under vacuum and the residue was subJect to ¹H NMR test to determine the ratio of **3aa-D**.

8.968 9.896 9.8966 9.89666 9.8966 9.8966 9.8966 9.8966 9.8966 9.8966 9.8966 9.8966



Figure S3. ¹H NMR spectrum of the mixture system of 3aa-D



In a 25 mL sealed tube, 1 mL EA was added to a mixture of 1-methyl-N-(quinolin-6-yl)-1H-indole-3-carboxamide **1a** (0.1 mmol, 1.0 equiv.), Co-2 (38.4 mg,1 equiv), Ag₂O (46.3 mg, 2.0 equiv.), CD₃COOD (40 equiv) under air. The tube was sealed with a Teflon lined cap and the reaction mixture was stirred at 100 °C by heating metal mantle for 12 h. After cooling to room temperature, the mixture was filtered over celite, concentrated under vacuum and the residue was subJect to ¹H NMR test to determine the ratio of **1a-D**.

8.210 8.206 8.189 8.186 8.186 8.186 7.943 7.622 7.602



Figure S4. ¹H NMR spectrum of the mixture system of 1a-D



In a 25 mL sealed tube, 1 mL EA was added to a mixture of 1-methyl-N-(quinolin-6-yl)-1H-indole-3-carboxamide **1a** (0.1 mmol, 1.0 equiv.), Co-2 (7.7 mg, 20 mol%), Ag₂O (46.3 mg, 2.0 equiv.), CH₃OH (10 equiv) under air. The tube was sealed with a Teflon lined cap and the reaction mixture was stirred at 100 °C by heating metal mantle for 12 h. After cooling to room temperature, the mixture was filtered over celite, concentrated under vacuum and the residue was subject to ¹H NMR test to determine the ratio of **3aa**. Yield were determined by ¹H NMR analysis and CH₂Br₂ were added as an inner standard.

In a 25 mL sealed tube, 1 mL EA was added to a mixture of **1a-D** (0.1 mmol, 1.0 equiv.), Co-2 (7.7 mg, 20 mol%), Ag₂O (46.3 mg, 2.0 equiv.), CH₃OH (10 equiv) under air. The tube was sealed with a Teflon lined cap and the reaction mixture was

stirred at 100 °C by heating metal mantle for 12 h. After cooling to room temperature, the mixture was filtered over celite, concentrated under vacuum and the residue was subject to ¹H NMR test to determine the ratio of **3aa**. Yield were determined by ¹H NMR analysis and CH_2Br_2 were added as an inner standard.



Figure S6. ¹H NMR spectrum of the 1a-D mixture system of 3aa



In a 25 mL sealed tube, 1 mL EA was added to a mixture of 1-methyl-N-(quinolin-6-yl)-1H-indole-3-carboxamide **1a** (0.1 mmol, 1.0 equiv.), Co-1 (18.4 mg, 50 mol%), Ag₂O (46.3 mg, 2.0 equiv.), CH₃OH (40 equiv) under air. The tube was sealed with a Teflon lined cap and the reaction mixture was stirred at 100 °C by heating metal mantle for 5 minute. After cooling to room temperature, Take out the appropriate reaction solution for HR-MS test, and then analyze and fit the spectrogram.



Figure S8. HR-MS of 3aa mixture system partial enlargement



Figure S9. HR-MS of 3aa mixture system partial enlargement



Figure S10. HRMS of origin fit spectrum

3. Characterization Data



2-methoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3aa)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3aa** (26 mg, 80 % yield), ¹H NMR (400 MHz, CDCl₃) δ 11.11 (s, 1H), 9.03 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.88 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.50 – 8.45 (m, 1H), 8.17 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.49 – 7.44 (m, 2H), 7.33 – 7.27 (m, 3H), 4.27 (s, 3H), 3.73 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.8, 153.7, 148.2, 139.0, 136.5, 136.0, 132.2, 128.3, 127.8, 125.3, 122.5, 122.3, 121.7, 121.6, 120.7, 116.4, 109.1, 95.7, 64.0, 28.3. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₀H₁₈N₃O₂⁺): 332.1394, found: 332.1386.



2-ethoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3ba)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3ba** (26 mg, 76 % yield), ¹H NMR (400 MHz, CDCl₃) δ 11.04 (s, 1H), 9.07 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.87 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.51 – 8.47 (m, 1H), 8.17 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.60 – 7.56 (m, 1H), 7.49 – 7.44 (m, 2H), 7.32 – 7.26 (m, 3H), 4.42 (q, *J* = 7.2 Hz, 2H), 3.71 (s, 3H), 1.64 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.1, 152.5, 148.0, 138.9, 136.5, 136.0, 132.3, 128.3, 127.8, 125.5, 122.4, 122.2, 121.8, 121.5, 120.6, 116.5, 109.1, 96.3, 73.5, 28.4, 15.5. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₁H₂₀N₃O₂⁺): 346.1550, found: 346.1540.



2-butoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (4ab)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 5/1/1) afforded the product as a solid **4ab** (26 mg, 71 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.96 (s, 1H), 9.09 – 9.04 (m, 1H), 8.85 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.50 – 8.45 (m, 1H), 8.17 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.50 – 7.44 (m, 2H), 7.31 – 7.26 (m, 3H), 4.35 (t, *J* = 6.8 Hz, 2H), 3.71 (s, 3H), 2.09 – 2.02 (m, 2H), 1.59 – 1.53 (m, 2H), 0.96 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.1, 152.8, 147.9, 139.0, 136.5, 136.0, 132.3, 128.3, 127.8, 125.5, 122.3, 122.2, 121.7, 121.5, 120.7, 116.6, 109.0, 96.1, 32.0, 28.4, 19.2, 14.1. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₃H₂₄N₃O₂⁺): 374.1863 found: 374.1853.



1-methyl-2-(octyloxy)-N-(quinolin-8-yl)-1H-indole-3-carboxamide (4ac)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 5/1/1) afforded the product as a solid **4ac** (28 mg, 66 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.97 (s, 1H), 9.07 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.86 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.50 – 8.44 (m, 1H), 8.18 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.51 – 7.45 (m, 2H), 7.32 – 7.28 (m, 3H), 4.33 (t, *J* = 6.8 Hz, 2H), 3.73 (s, 3H),2.11 – 2.03 (m, 2H), 1.53 – 1.47 (m, 2H), 1.33 – 1.22 (m, 8H), 0.86 (t, *J* = 6.8 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.1, 152.8, 147.9, 139.0, 136.5, 136.0, 132.3, 128.3, 127.8, 125.5, 122.4, 122.2, 121.7, 121.5, 120.7, 116.6, 109.0, 96.2, 31.9, 30.0, 29.6, 29.3, 28.4, 25.9, 22.7, 14.2. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₇H₃₂N₃O₂⁺): 430.2489, found: 430.2481.



1-methyl-2-(4-phenylbutoxy)-N-(quinolin-8-yl)-1H-indole-3-carboxamide (4ad) Prepared according to general procedure 2.4, purification of the residue by preparative chromatography (PE/DCM/EA = 5/1/1) afforded the product as a solid 4ad (18 mg, 40 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.95 (s, 1H), 9.06 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.57 (dd, *J* = 4.2, 1.6 Hz, 1H), 8.49 – 8.45 (m, 1H), 8.16 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.48 (dd, J = 8.0, 0.8 Hz, 1H), 7.39 (dd, J = 8.0, 4.0 Hz, 1H), 7.31 – 7.25 (m, 5H), 7.21 (d, J = 7.2 Hz, 1H), 7.16 – 7.12 (m, 2H), 4.34 (t, J = 6.8 Hz, 2H), 3.70 (s, 3H), 2.68 (t, J = 7.5 Hz, 2H), 2.15 – 2.08 (m, 2H), 1.92 – 1.85 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 163.0, 152.7, 148.0, 141.8, 138.9, 136.4, 136.0, 132.2, 128.6, 128.3, 127.8, 126.1, 125.5, 122.4, 122.2, 121.8, 121.6, 120.7, 116.6, 109.1, 96.2, 35.9, 29.6, 28.4, 27.8. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₉H₂₈N₃O₂⁺): 450.2176, found: 450.2168.



2-(4-methoxybutoxy)-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (4ae) Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 5/1/1) afforded the product as a solid **4ae** (20 mg, 49 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.96 (s, 1H), 9.06 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.87 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.49 – 8.45 (m, 1H), 8.18 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.50 – 7.45 (m, 2H), 7.32 – 7.27 (m, 3H), 4.38 (t, *J* = 6.8 Hz, 2H), 3.73 (s, 3H), 3.41 (t, *J* = 6.4 Hz, 2H), 3.30 (s, 3H), 2.20 – 2.13 (m, 2H), 1.85 – 1.79 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 163.1, 152.8, 148.0, 139.0, 136.5, 136.0, 132.3, 128.3, 127.8, 125.5, 122.4, 122.2, 121.7, 121.6, 120.7, 116.6, 109.1, 96.2, 72.4, 58.8, 28.4, 27.0, 26.2. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₄H₂₆N₃O₃⁺): 404.1969, found: 404.1957.



2-(3-hydroxypropoxy)-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (4ah)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 1/1/1) afforded the product as a solid **4ah** (13 mg, 34 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.84 (s, 1H), 9.01 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.82 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.43 (dd, *J* = 6.8, 1.6 Hz, 1H), 8.15 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.59 – 7.55 (m, 1H), 7.47 (dd, *J* = 8.2, 1.2 Hz, 1H), 7.42 (dd, *J* = 8.2, 4.2 Hz, 1H), 7.35 – 7.26 (m, 3H), 4.44 (t, *J* = 6.0 Hz, 2H), 4.00 (t, *J* = 5.6 Hz, 2H), 3.64 (s, 3H), 2.25 – 2.19 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 163.2, 153.5, 148.1, 138.8,

136.5, 135.7, 132.1, 128.2, 127.8, 124.8, 122.3, 122.3, 121.6, 121.0, 120.9, 116.7, 109.4, 96.0, 74.1, 58.8, 32.7, 28.2. HRMS (ESI+) exact mass calculated for $[M+H]^+$ ($C_{22}H_{22}N_3O_3^+$): 376.1656, found: 376.1645.



2-(3-chloropropoxy)-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (4ag)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 5/1/1) afforded the product as a solid **4ag** (20 mg, 51 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.89 (s, 1H), 9.07 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.82 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.50 – 8.45 (m, 1H), 8.19 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.62 – 7.58 (m, 1H), 7.51 – 7.45 (m, 2H), 7.33 – 7.28 (m, 3H), 4.49 (t, *J* = 6.0 Hz, 2H), 3.95 (t, *J* = 6.0 Hz, 2H), 3.76 (s, 3H), 2.57 – 2.51 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 162.9, 152.2, 147.9, 138.8, 136.6, 135.9, 132.3, 128.3, 127.9, 125.3, 122.6, 122.3, 121.7, 121.6, 120.8, 116.7, 109.2, 96.3, 73.5, 41.3, 32.6, 28.4. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₂H₂₁ClN₃O₂⁺): 394.1317, found: 394.1306.



1-methyl-N-(quinolin-8-yl)-2-(2,2,2-trichloroethoxy)-1H-indole-3-carboxamide (4af)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 4/1/1) afforded the product as a solid **4af** (35 mg, 77 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.61 (s, 1H), 8.93 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.89 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.36 – 8.33 (m, 1H), 8.20 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.63 – 7.59 (m, 1H), 7.53 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.49 (dd, *J* = 8.4, 4.0 Hz, 1H), 7.39 – 7.33 (m, 3H), 5.21 (s, 2H), 3.83 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.6, 154.0, 148.5, 138.9, 136.5, 135.5, 131.7, 128.3, 127.7, 123.9, 122.4, 122.3, 121.8, 121.2, 119.8, 116.5, 109.7, 95.9, 94.4, 85.7, 28.9. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₁H₁₇Cl₃N₃O₂⁺): 448.0381, found: 448.0369.



2-(3-bromopropoxy)-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (4aj)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 5/1/1) afforded the product as a solid **4aj** (23 mg, 53 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.87 (s, 1H), 9.07 (dd, J = 7.6, 1.2 Hz, 1H), 8.83 (dd, J = 4.0, 1.6 Hz, 1H), 8.49 – 8.45 (m, 1H), 8.19 (dd, J = 8.4, 1.6 Hz, 1H), 7.62 – 7.58 (m, 1H), 7.51 – 7.46 (m, 2H), 7.33 – 7.28 (m, 3H), 4.49 (t, J = 5.6 Hz, 2H), 3.79 (t, J = 6.4 Hz, 2H), 3.77 (s, 3H), 2.65 – 2.59 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 162.9, 152.2, 147.9, 138.9, 136.6, 135.9, 132.3, 128.3, 127.9, 125.3, 122.6, 122.3, 121.7, 121.6, 120.8, 116.7, 109.2, 96.3, 74.6, 32.8, 29.7, 28.5. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₂H₂₁BrN₃O₂⁺): 438.0812, found: 438.0801.



2-(2,2-difluoroethoxy)-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (4ai) Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 4/1/1) afforded the product as a solid **4ai** (26 mg, 71 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.74 (s, 1H), 8.99 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.86 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.44 – 8.40 (m, 1H), 8.20 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.62 – 7.58 (m, 1H), 7.53 – 7.47 (m, 1H), 7.36 – 7.30 (m, 3H), 6.39 4.67 (tt, *J* = 54.8, 3.6 Hz, 1H)), 4.67 (td, *J* = 13.6, 3.8 Hz, 2H), 3.75 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.5, 152.2, 148.2, 138.9, 136.6, 135.6, 132.0, 128.3, 127.8, 124.5, 122.7, 122.5, 121.7, 121.1, 121.0, 116.6, 113.4 (t, *J* = 242.4 Hz), 109.5, 95.9, 74.1 (t, *J* = 28.3 Hz), 28.3. ¹⁹F NMR (377 MHz, CDCl₃) δ -126.23. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₁H₁₈F₂N₃O₂⁺): 382.1362, found: 382.1350.



1-methyl-2-((4-oxopentyl)oxy)-N-(quinolin-8-yl)-1H-indole-3-carboxamide (4ak) Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 5/1/1) afforded the product as a solid **4ak** (10 mg, 26 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.88 (s, 1H), 9.05 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.87 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.48 – 8.43 (m, 1H), 8.19 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.62 – 7.58 (m, 1H), 7.51 – 7.46 (m, 2H), 7.33 – 7.27 (m, 3H), 4.36 (t, *J* = 6.8 Hz, 2H), 3.72 (s, 3H), 2.74 (t, J = 7.2 Hz, 2H), 2.38 – 2.31 (m, 2H), 2.10 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 207.7, 163.0, 152.5, 148.1, 138.9, 136.6, 135.9, 132.3, 128.3, 127.9, 125.4, 122.5, 122.2, 121.6, 120.8, 116.7, 109.1, 96.2, 76.5, 39.6, 30.1, 28.5, 24.0. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C2₄H₂₄N₃O₃⁺): 402.1812, found: 402.1801.



1-methyl-N-(quinolin-8-yl)-2-(2,2,3-trifluorobutoxy)-1H-indole-3-carboxamide (4am)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 5/1/1) afforded the product as a solid **4am** (37 mg, 79 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.61 (s, 1H), 8.95 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.86 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.37 (dd, *J* = 6.0, 2.4 Hz, 1H), 8.20 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.60 (t, *J* = 8.0 Hz, 1H), 7.53 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.48 (dd, *J* = 8.4, 4.2 Hz, 1H), 7.39 – 7.32 (m, 3H), 5.41 – 5.22 (m, 1H), 5.10 – 4.99 (m, 1H), 4.83 – 4.74 (m, 1H), 3.73 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.4, 152.5, 148.7, 138.8, 136.6, 135.4, 131.8, 128.3, 127.7, 123.9, 122.7, 122.5, 121.8, 121.3, 120.4, 116.6, 109.7, 95.9, 85.4 – 84.5 (m), 83.2 – 82.5 (m), 72.80 – 72.23 (m), 28.28. ¹⁹F NMR (377 MHz, CDCl₃) δ -73.84 (dd, *J* = 21.0, 10.5 Hz), -115.74 – -115.96 (m), -116.48 – -116.74 (m), -120.90 – -121.14 (m), -121.64 – -121.87 (m), -211.8 – -212.0 (m). HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₃H₁₈F₆N₃O₂⁺): 482.1298, found:482.1286.



2-((6-chlorohexyl)oxy)-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (4ai)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 5/1/1) afforded the product as a solid **4ai** (20 mg, 46 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.93 (s, 1H), 9.06 (d, *J* = 7.6 Hz, 1H), 8.87 - 8.84 (m, 1H), 8.48 - 8.43 (m, 1H), 8.21 - 8.17 (m, 1H), 7.62 - 7.58 (m, 1H), 7.51 - 7.46 (m, 2H), 7.34 - 7.27 (m, 3H), 4.35 (t, *J* = 6.8 Hz, 2H), 3.73 (s, 3H), 3.48 (t,

J = 6.8 Hz, 2H), 2.12 – 2.05 (m, 2H), 1.75 – 1.69 (m, 2H), 1.56 – 1.46 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 163.0, 152.7, 148.0, 138.9, 136.5, 136.0, 132.3, 128.3, 127.9, 125.5, 122.4, 122.2, 121.7, 121.6, 120.7, 116.6, 109.1, 96.2, 45.0, 32.5, 29.9, 28.4, 26.8, 25.3. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₅H₂₇ClN₃O₂⁺): 436.1786, found: 436.1772.



2-(3-hydroxybutoxy)-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (4an) Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 1/1/1) afforded the product as a solid **4an** (16 mg, 42 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.82 (s, 1H), 9.01 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.80 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.43 (dd, *J* = 7.2, 1.2 Hz, 1H), 8.13 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.57 – 7.53 (m, 1H), 7.46 (dd, *J* = 8.2, 1.2 Hz, 1H), 7.41 (dd, *J* = 8.2, 4.0 Hz, 1H), 7.33 – 7.26 (m, 2H), 7.24 – 7.21 (m, 1H), 4.55 – 4.50 (m, 1H), 4.35 – 4.26 (m, 2H), 3.63 (s, 3H), 2.27 – 2.19 (m, 1H), 1.97 – 1.90 (m, 1H), 1.30 (d, *J* = 6.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.1, 153.5, 148.1, 138.8, 136.5, 135.7, 132.1, 128.2, 127.7, 124.8, 122.3, 122.2, 121.6, 121.0, 120.9, 116.7, 109.3, 95.9, 74.5, 64.3, 39.0, 28.2, 23.9. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₃H₂₄N₃O₃⁺): 390.1812, found: 390.1808.



2-ethoxy-1,4-dimethyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3ca)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3ca** (20 mg, 56 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.63 (s, 1H), 9.02 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.82 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.17 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.50 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.44 (dd, *J* = 8.4, 4.0 Hz, 1H), 7.19 – 7.14 (m, 1H), 7.09 (d, *J* = 7.6 Hz, 1H), 7.00 (d, *J* = 7.2 Hz, 1H), 4.32 (q, *J* = 7.2 Hz, 2H), 3.67 (s, 3H), 2.75 (s, 3H), 1.39 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.6, 151.9, 148.2, 138.9, 136.4, 135.7, 132.4, 131.7, 128.3, 127.8, 123.8, 123.7, 122.0,

121.6, 121.0, 116.4, 106.7, 97.7, 72.6, 28.2, 22.0, 15.5. HRMS (ESI+) exact mass calculated for $[M+H]^+$ ($C_{22}H_{22}N_3O_2^+$): 360.1707, found: 360.1705.



2-ethoxy-4-fluoro-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3da)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3da** (29 mg, 84 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.86 (s, 1H), 9.05 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.84 (dd, *J* = 4.2, 1.6 Hz, 1H), 8.16 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.60 – 7.56 (m, 1H), 7.49 (dd, *J* = 8.2, 1.2 Hz, 1H), 7.44 (dd, *J* = 8.4, 4.0 Hz, 1H), 7.21 – 7.16 (m, 1H), 7.06 – 7.03 (m, 1H), 6.96 (ddd, *J* = 11.6, 8.0, 0.8 Hz, 1H), 4.45 (q, *J* = 7.2 Hz, 2H), 3.68 (s, 3H), 1.50 (t, *J* = 6.8 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 161.9, 156.2 (*J* = 249.5 Hz), 153.4, 148.1, 139.0, 136.4, 135.9, 134.5, 134.4, 128.2, 127.7, 122.6, 122.5, 121.5, 120.9, 116.8, 112.7 (*J* = 19.2 Hz), 108.1 (*J* = 22.2 Hz), 105.3, 95.5, 72.9, 28.6, 15.5. ¹⁹F NMR (377 MHz, CDCl₃) δ -112.85. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₁H₁₉FN₃O₂⁺): 364.1456, found: 364.1444



2-ethoxy-5-methoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3ea) Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3ea** (32 mg, 86 % yield), ¹H NMR (400 MHz, CDCl₃) δ 11.03 (s, 1H), 9.06 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.86 (dd, *J* = 4.2, 1.6 Hz, 1H), 8.17 (dd, *J* = 8.4, 1.6 Hz, 1H), 8.04 (d, *J* = 2.4 Hz, 1H), 7.60 – 7.56 (m, 1H), 7.50 – 7.44 (m, 2H), 7.15 (d, *J* = 8.8 Hz, 1H), 6.91 (dd, *J* = 8.8, 2.4 Hz, 1H), 4.41 (q, *J* = 6.8 Hz, 2H), 3.94 (s, 3H), 3.68 (s, 3H), 1.64 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.3, 156.1, 152.5, 148.0, 139.0, 136.5, 136.0, 128.3, 127.8, 127.0, 126.1, 121.6, 120.6, 116.5, 112.7, 110.0, 103.4, 96.3, 73.5, 56.0, 28.5, 15.5. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₂H₂₂N₃O₃⁺): 376.1656, found: 376.1653.



2-ethoxy-1,5-dimethyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3fa)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3fa** (24 mg, 69 % yield), ¹H NMR (400 MHz, CDCl₃) δ 11.03 (s, 1H), 9.08 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.87 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.34 – 8.30 (m, 1H), 8.17 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.49 – 7.44 (m, 2H), 7.15 (d, *J* = 8.0 Hz, 1H), 7.10 (dd, *J* = 8.4, 1.2 Hz, 1H), 4.43 (q, *J* = 7.2 Hz, 2H), 3.69 (s, 3H), 2.51 (s, 3H), 1.64 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.2, 152.5, 148.0, 139.0, 136.5, 136.1, 131.7, 130.6, 128.3, 127.8, 125.6, 123.7, 121.7, 121.5, 120.6, 116.5, 108.8, 95.9, 76.8, 73.4, 28.4, 21.8, 15.5. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₂H₂₂N₃O₂⁺): 360.1707, found: 360.1706.



5-chloro-2-ethoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3ga)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3ga** (28 mg, 75 % yield), ¹H NMR (400 MHz, CDCl₃) δ 11.00 (s, 1H), 9.03 (d, J = 7.2 Hz, 1H), 8.86 (dd, J = 4.2, 1.6 Hz, 1H), 8.42 – 8.37 (m, 1H), 8.17 (dd, J = 8.2, 1.6 Hz, 1H), 7.60 – 7.56 (m, 1H), 7.50 – 7.44 (m, 2H), 7.27 – 7.24 (m, 2H), 4.43 (q, J = 7.2 Hz, 2H), 3.67 (s, 3H), 1.64 (t, J = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.6, 152.6, 148.1, 138.9, 136.5, 135.8, 132.8, 128.3, 128.3, 127.8, 124.0, 122.9, 122.7, 121.6, 120.9, 116.6, 109.3, 96.6, 73.7, 28.5, 15.5. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₁H₁₉ClN₃O₂⁺): 380.1160, found: 380.1156.



5-bromo-2-ethoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3ha) Prepared according to general procedure **2.4**, purification of the residue by preparative

chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3ha** (31 mg,

76 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.95 (s, 1H), 9.02 (dd, J = 7.6, 1.2 Hz, 1H), 8.85 (dd, J = 4.0, 1.6 Hz, 1H), 8.65 (d, J = 1.6 Hz, 1H), 8.16 (dd, J = 8.4, 1.6 Hz, 1H), 7.59 – 7.55 (m, 1H), 7.49 – 7.43 (m, 2H), 7.32 (dd, J = 8.4, 2.0 Hz, 1H), 7.07 (d, J = 8.4 Hz, 1H), 4.41 (q, J = 7.0 Hz, 2H), 3.66 (s, 3H), 1.63 (t, J = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.5, 152.8, 148.0, 138.9, 136.5, 135.8, 130.9, 128.3, 127.8, 127.0, 125.3, 124.3, 121.6, 120.8, 116.5, 115.6, 110.5, 96.1, 73.7, 28.5, 15.5. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₁H₁₉BrN₃O₂⁺): 424.0655, found: 424.0652.



6-chloro-2-ethoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3ia) Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3ia** (27 mg, 72 % yield), ¹H NMR (400 MHz, CDCl₃) δ 11.00 (s, 1H), 9.03 (d, *J* = 7.2 Hz, 1H), 8.86 (dd, *J* = 4.2, 1.6 Hz, 1H), 8.42 – 8.37 (m, 1H), 8.17 (dd, *J* = 8.2, 1.6 Hz, 1H), 7.60 – 7.56 (m, 1H), 7.50 – 7.44 (m, 2H), 7.27 – 7.24 (m, 2H), 4.43 (q, *J* = 7.2 Hz, 2H), 3.67 (s, 3H), 1.64 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.6, 152.6, 148.1, 138.9, 136.5, 135.8, 132.8, 128.3, 128.3, 127.8, 124.0, 122.9, 122.7, 121.6, 120.9, 116.6, 109.3, 96.6, 73.7, 28.5, 15.5. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₁H₁₉ClN₃O₂⁺): 380.1160, found: 380.1164.



6-bromo-2-ethoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3ja)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3ja** (29 mg, 71 % yield), ¹H NMR (400 MHz, CDCl₃) δ 11.00 (s, 1H), 9.03 (dd, *J* = 7.7, 1.3 Hz, 1H), 8.87 (dd, *J* = 4.2, 1.6 Hz, 1H), 8.35 (d, *J* = 8.4 Hz, 1H), 8.18 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.58 (d, *J* = 8.0 Hz, 1H), 7.51 – 7.45 (m, 2H), 7.42 – 7.38 (m, 2H), 4.44 (q, *J* = 6.8 Hz, 2H), 3.69 (s, 3H), 1.65 (t, *J* = 6.8 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.6, 152.5, 148.1, 138.9, 136.5, 135.8, 133.1, 128.3, 127.8, 125.3, 124.4, 123.2,

121.6, 120.9, 116.6, 115.8, 112.2, 96.6, 73.7, 28.5, 15.5. HRMS (ESI+) exact mass calculated for $[M+H]^+$ (C₂₁H₁₉BrN₃O₂⁺): 424.0655, found: 424.0649.



2-ethoxy-6-methoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3ka) Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3ka** (28 mg, 76 % yield), ¹H NMR (400 MHz, CDCl₃) δ 11.01 (s, 1H), 9.05 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.87 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.36 (d, *J* = 8.8 Hz, 1H), 8.17 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.60 – 7.66 (m, 1H), 7.49 – 7.44 (m, 2H), 6.95 (dd, *J* = 8.7, 2.3 Hz, 1H), 6.75 (d, *J* = 2.4 Hz, 1H), 4.41 (q, *J* = 7.2 Hz, 2H), 3.89 (s, 3H), 3.67 (s, 3H), 1.64 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.1, 156.7, 151.8, 148.0, 139.0, 136.5, 136.1, 133.1, 128.3, 127.8, 122.6, 121.5, 120.6, 119.3, 116.5, 110.7, 96.2, 93.8, 73.5, 55.9, 28.4, 15.5. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₂H₂₂N₃O₃⁺): 376.1656, found: 376.1653.



2-ethoxy-1,7-dimethyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3la)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3la** (27 mg, 79 % yield), ¹H NMR (400 MHz, CDCl₃) δ 11.08 (s, 1H), 9.08 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.88 (dd, *J* = 4.2, 1.6 Hz, 1H), 8.40 (d, *J* = 8.0 Hz, 1H), 8.18 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.51 – 7.45 (m, 2H), 7.17 – 7.14 (m, 1H), 6.99 (d, *J* = 7.2 Hz, 1H), 4.40 (q, *J* = 6.8 Hz, 2H), 3.97 (s, 3H), 2.77 (s, 3H), 1.66 (t, *J* = 6.8 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.1, 152.5, 148.0, 139.0, 136.5, 136.1, 131.4, 128.3, 127.8, 126.3, 125.4, 122.0, 121.5, 120.8, 120.6, 119.1, 116.5, 96.2, 73.4, 31.3, 19.9, 15.4. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₂H₂₂N₃O₂⁺): 360.1707, found: 360.1704.



7-chloro-2-ethoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3ma)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3ma** (27 mg, 73 % yield), ¹H NMR (400 MHz, CDCl₃) δ 11.08 (s, 1H), 9.05 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.88 (dd, *J* = 4.2, 1.6 Hz, 1H), 8.45 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.19 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.52 – 7.46 (m, 2H), 7.22 – 7.19 (m, 1H), 7.18 – 7.14 (m, 1H), 4.43 (q, *J* = 6.8 Hz, 2H), 4.07 (s, 3H), 1.67 (t, *J* = 6.8 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.5, 153.0, 148.1, 138.9, 136.5, 135.8, 128.4, 128.3, 127.8, 124.1, 122.6, 121.6, 120.9, 120.6, 116.6, 96.8, 73.8, 31.4, 15.4. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₁H₁₉ClN₃O₂⁺): 380.1160, found: 380.1158.



2-ethoxy-1-propyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3na)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3na** (29 mg, 79 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.96 (s, 1H), 9.07 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.87 (dd, *J* = 4.2, 1.6 Hz, 1H), 8.50 – 8.46 (m, 1H), 8.17 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.49 – 7.44 (m, 2H), 7.32 – 7.25 (m, 3H), 4.44 (q, *J* = 6.8 Hz, 2H), 4.11 – 4.05 (m, 2H), 1.91 (dt, *J* = 14.8, 7.6 Hz, 2H), 1.63 (t, *J* = 6.8 Hz, 3H), 1.01 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.1, 152.7, 148.0, 138.9, 136.5, 136.0, 131.5, 128.3, 127.8, 125.7, 122.2, 122.0, 121.6, 121.5, 120.6, 116.5, 109.5, 96.1, 73.4, 44.0, 23.1, 15.6, 11.7. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₃H₂₄N₃O₂⁺): 374.1863, found: 374.1860.



1-benzyl-2-ethoxy-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3oa)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **30a** (33 mg, 81 % yield), ¹H NMR (400 MHz, CDCl₃) δ 11.01 (s, 1H), 9.08 (dd, *J* = 7.6, 1.0 Hz, 1H), 8.86 (dd, *J* = 4.2, 1.6 Hz, 1H), 8.51 (d, *J* = 8.0 Hz, 1H), 8.18 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.62 – 7.58 (m, 1H), 7.48 (ddd, *J* = 12.4, 8.2, 2.6 Hz, 2H), 7.35 – 7.27 (m, 4H), 7.23 – 7.14 (m, 4H), 5.37 (s, 2H), 4.33 (q, *J* = 6.8 Hz, 2H), 1.53 (t, *J* = 6.8 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.0, 152.7, 148.1, 139.0, 136.7, 136.5, 136.0, 132.0, 129.1, 128.3, 127.9, 126.5, 125.7, 122.6, 122.3, 121.7, 121.6, 120.7, 116.6, 109.9, 96.7, 73.8, 45.6, 15.5. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₇H₂₄N₃O₂⁺): 422.1863, found: 422.1860.



2-ethoxy-1-(naphthalen-1-ylmethyl)-N-(quinolin-8-yl)-1H-indole-3-carboxamide (3pa)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3pa** (35 mg, 76 % yield), ¹H NMR (400 MHz, CDCl₃) δ 11.08 (s, 1H), 9.10 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.83 (dd, *J* = 4.2, 1.6 Hz, 1H), 8.56 (d, *J* = 8.0 Hz, 1H), 8.19 – 8.13 (m, 2H), 7.96 (d, *J* = 8.0 Hz, 1H), 7.79 (d, *J* = 8.2 Hz, 1H), 7.70 – 7.65 (m, 1H), 7.63 – 7.59 (m, 2H), 7.50 (dd, *J* = 8.2, 1.2 Hz, 1H), 7.44 (dd, *J* = 8.0, 4.2 Hz, 1H), 7.31 (td, *J* = 8.0, 4.0 Hz, 2H), 7.20 – 7.15 (m, 1H), 7.06 (d, *J* = 8.0 Hz, 1H), 6.80 (dd, *J* = 7.2, 0.8 Hz, 1H), 4.32 (q, *J* = 7.2 Hz, 2H), 1.42 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.1, 152.8, 148.0, 139.0, 136.5, 136.0, 133.8, 132.3, 131.6, 130.4, 129.3, 128.3, 127.9, 126.9, 126.3, 125.8, 125.7, 123.2, 122.7, 122.4, 122.2, 121.9, 121.6, 120.8, 116.6, 110.0, 97.0, 74.0, 43.4, 15.5. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₃₁H₂₆N₃O₂⁺): 472.2020, found: 472.2021.



3-ethoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-2-carboxamide (3ta)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3ta** (27 mg, 80 % yield), ¹H NMR (400 MHz, CDCl₃) δ 11.93 (s, 1H), 9.01 (dd, *J* = 7.6, 1.4 Hz, 1H), 8.91 (dd, *J* = 4.2, 1.6 Hz, 1H), 8.18 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.78 (d, *J* = 8.0 Hz, 1H), 7.60 – 7.56 (m, 1H), 7.52 (dd, *J* = 8.0, 1.4 Hz, 1H), 7.47 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.42 (d, *J* = 8.4 Hz, 1H), 7.37 – 7.32 (m, 1H), 7.13 (ddd, *J* = 8.0, 6.8, 1.0 Hz, 1H), 4.58 (q, *J* = 7.2 Hz, 2H), 4.19 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 160.8, 148.2, 141.1, 139.3, 136.9, 136.4, 135.9, 128.3, 127.6, 125.1, 121.7, 121.4, 120.0, 119.8, 119.5, 118.7, 117.1, 110.5, 71.1, 32.2, 15.8. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₁H₂₀N₃O₂⁺): 346.1550, found: 346.1546.



5-ethoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-6-carboxamide (3ua)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3ua** (25 mg, 74 % yield), ¹H NMR (400 MHz, CDCl₃) δ 12.35 (s, 1H), 9.16 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.87 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.44 (s, 1H), 8.18 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.63 – 7.59 (m, 1H), 7.53 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.47 (dd, *J* = 8.4, 4.0 Hz, 1H), 7.23 (s, 1H), 7.18 (d, *J* = 2.8 Hz, 1H), 6.43 (dd, *J* = 2.8, 0.4 Hz, 1H), 4.42 (q, *J* = 7.2 Hz, 2H), 3.87 (s, 3H), 1.77 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 165.3, 151.9, 147.9, 139.6, 136.5, 136.3, 132.6, 132.2, 131.9, 128.3, 127.8, 121.5, 121.4, 117.9, 117.8, 114.0, 103.1, 100.4, 65.8, 33.4, 15.3. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₁H₂₀N₃O₂⁺): 346.1550, found: 346.1541.



6-ethoxy-1-methyl-N-(quinolin-8-yl)-1H-indole-5-carboxamide (3va)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3va** (37 mg, 52% yield), ¹H NMR (400 MHz, CDCl₃) δ 11.97 (s, 1H), 10.02 (s, 1H), 9.18 (s, 1H), 9.16 (d, J = 7.6 Hz, 1H), 8.82 (dd, J = 4.0, 1.6 Hz, 1H), 8.18 (dd, J = 8.0, 1.6 Hz, 1H), 7.60 (d, J = 6.4 Hz, 2H), 7.53 (d, J = 7.2 Hz, 1H), 7.45 (dd, J = 8.0, 4.0 Hz, 1H), 6.87

(s, 1H), 4.43 - 4.38 (m, 2H), 3.85 (s, 3H), 1.78 (t, J = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 184.1, 164.5, 155.3, 147.8, 140.5, 139.4, 138.6, 136.4, 136.3, 128.3, 127.9, 126.7, 121.5, 119.8, 119.5, 118.9, 118.0, 117.9, 93.1, 65.8, 34.0, 29.9, 15.1. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₁H₂₀N₃O₂⁺): 346.1550, found: 346.1543.



1,1'-dimethyl-N3,N3'-di(quinolin-8-yl)-1H,1'H-[2,2'-biindole]-3,3'-dicarboxamide (3a')

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **3a'** (19 mg, 32 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.33 (s, 2H), 8.91-8.88 (m, 4H), 7.91 (dd, J = 8.4 Hz, 1.6 Hz, 2H), 7.52-7.40 (m, 10H), 7.32 (dd, J = 8.0 Hz, 0.8 Hz, 2H), 7.10 (dd, J = 8.0 Hz, 2.0 Hz, 2H), 3.65 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 162.7, 148.1, 138.6, 138.5, 135.7, 135.2, 128.9, 128.0, 127.7, 127.2, 124.4, 123.4, 122.6, 121.4, 121.0, 116.2, 114.7, 110.4, 30.9. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₃₈H₂₉N₆O₂⁺): 601.2347, found: 601.2341.



1-(4-chlorobenzyl)-2-methoxy-N-(quinolin-8-yl)-1H-indole-3-carboxamide (6)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 3/1/1) afforded the product as a solid **6** (36 mg, 81 % yield), ¹H NMR (400 MHz, CDCl₃) δ 11.03 (s, 1H), 9.04 (d, *J* = 7.6 Hz, 1H), 8.85 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.49 (d, *J* = 8.0 Hz, 1H), 8.17 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.49 (d, *J* = 7.6 Hz, 1H), 7.45 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.32 – 7.27 (m, 3H), 7.24 – 7.20 (m, 1H), 7.13 – 7.09 (m, 3H), 5.32 (s, 2H), 4.15 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.6, 153.7, 148.2, 139.0, 136.5, 135.8, 135.1, 133.8, 131.6, 129.3, 128.3, 127.9, 127.8, 125.5, 122.8, 122.5, 121.7, 121.6, 120.8, 116.5,

109.7, 96.2, 64.5, 44.9. HRMS (ESI+) exact mass calculated for $[M+H]^+$ (C₂₆H₂₁ClN₃O₂⁺): 442.1317, found: 442.1315.



2-((3,7-dimethyloct-6-en-1-yl)oxy)-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carbo xamide (7)

Prepared according to general procedure **2.4**, purification of the residue by preparative chromatography (PE/DCM/EA = 6/1/1) afforded the product as a solid **7** (15 mg, 34 % yield), ¹H NMR (400 MHz, CDCl₃) δ 10.95 (s, 1H), 9.07 (dd, *J* = 7.6, 1.2 Hz, 1H), 8.86 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.49 – 8.45 (m, 1H), 8.18 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.50 – 7.44 (m, 2H), 7.32 – 7.27 (m, 3H), 5.05 – 5.00 (m, 1H), 4.41 – 4.36 (m, 2H), 3.72 (s, 3H), 2.18 – 2.10 (m, 1H), 2.05 – 1.83 (m, 4H), 1.65 (d, *J* = 0.8 Hz, 3H), 1.54 (s, 3H), 1.38 – 1.33 (m, 1H), 1.21 – 1.15 (m, 1H), 0.90 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.1, 152.9, 148.0, 139.0, 136.5, 136.0, 132.3, 131.7, 128.3, 127.8, 125.5, 124.5, 122.4, 122.2, 121.7, 121.5, 120.7, 116.6, 109.0, 96.2, 76.5, 37.3, 36.9, 29.4, 28.4, 25.8, 25.4, 19.6, 17.8. HRMS (ESI+) exact mass calculated for [M+H]⁺ (C₂₉H₃₄N₃O₂⁺): 456.2646, found: 456.2639.

4. References

- (1) Chen, H.; Lin, C.; Xiong, C.; Liu, Z.; Zhang, Y. Org. Chem. Front. 2017, 4, 455-459.
- (2) Zhang, T.-Y.; Liu, C.; Chen, C.; Liu, J.-X.; Xiang, H.-Y.; Jiang, W.; Ding, T.-M.; Zhang, S.-Y. Org. Lett. 2018, 20, 220-223.
- (3) Pan, J.-L.; Chen, C.; Ma, Z.-J.; Zhou, J.; Wang, L.-R.; Zhang, S.-Y. Org. Lett. 2017, 19, 5216 5219.
- (4) Affron, D. P.; Davis, O. A.; Bull, J. A. Org. Lett. 2014, 16, 4956–4959.
- (5) Chen, K.; Hu, F.; Zhang, S.-Q.; Shi, B.-F. Chem. Sci., 2013, 4, 3906-3911.
- (6) Dhinagaran, G.; Prashanna Suvaitha, S.; Muthukumaran, M.; Venkatachalamet K. *Catal Lett.* 2021, 151, 1361-1375.
5. Crystallographic Data

X-ray data for 3aa

3aa	CCDC 2291138
compound	3 aa
formula	$C_{20}H_{16}N_3O_2$
formula weight	330.36
<i>T</i> (K)	298
crystal system	monoclinic
space group	P 1 21/c 1
<i>a</i> (Å)	7.9810(5)
b (Å)	10.9216(9)
<i>c</i> (Å)	19.0174(17)
α (°)	90
β (°)	96.715(7)
γ (°)	90
$V(Å^3)$	1646.3(2)
Ζ	4
D_{c} .(g cm ⁻³)	1.333
μ (mm ⁻¹)	0.713
reflns coll.	11451
independent reflns	3222
${}^{a}R_{I}$ [I $\geq 2 \sigma$ (I)]	0.0696
${}^{b}wR_{2}(all data)$	0.2006
GOF	1.041
${}^{a}R_{1} = \Sigma / F_{o} - F_{c} / \Sigma / F_{o} , \ {}^{b}wR_{2} = [\Sigma w (F_{o}{}^{2} - F_{c}{}^{2})^{2} / \Sigma w (F_{o}{}^{2})^{2}]^{1}$	

X-ray data for Co-2



crystal system	triclinic
space group	P-1
<i>a</i> (Å)	6.3806(2)
<i>b</i> (Å)	9.3454(3)
<i>c</i> (Å)	9.8157(2)
α (°)	91.120(2)
β (°)	98.754(2)
γ (°)	108.211(3)
$V(Å^3)$	548.10(3)
Z	2
$D_{c.}(g \text{ cm}^{-3})$	1.564
μ (mm ⁻¹)	8.732
reflns coll.	9647
independent reflns	2166
${}^{a}R_{I}$ [I $\geq 2 \sigma$ (I)]	0.0410
$^{b}wR_{2}(all data)$	0.1091
GOF	1.040
${}^{a}R_{1} = \Sigma / F_{o} - F_{c} / \Sigma / F_{o} , \ {}^{b}wR_{2} = [\Sigma w (F_{o}^{2} - F_{c}^{2})^{2} / \Sigma w (F_{o}^{2})^{2}]^{1}$	

6. NMR Spectra

11.111 11.111 11.111 11.111 11.111 11.111 11.111 11.111 11.111 11.111 11.111 11.111 11.111 11.111 11.111 12.025



11.042 9.064 9.064 9.064 9.064 8.875 8.875 8.875 8.864 8.875 8.843 8.843 8.8485 7.4487 7.7533 7.7553 7.75555 7.7555 7.7555 7.75555 7.75555 7.75555 7.75555 7.75555 7.75555 7.75555 7.75555



(10.963) (10.964) (10.963) (10.964) (10.963) (10.964)(10.









$\begin{array}{c} 10.869\\ 9.075\\ 9.075\\ 9.075\\ 8.837\\ 8.837\\ 8.8337\\ 8.8337\\ 8.8337\\ 8.8337\\ 8.8337\\ 8.8337\\ 8.8337\\ 8.8337\\ 8.849\\ 8.840\\ 8.849\\ 8.840\\$











$\begin{array}{c} 10.738\\ 9.003\\ 8.865\\ 8.865\\ 8.865\\ 8.854\\ 8.855\\ 8.855\\ 8.855\\ 8.855\\ 8.855\\ 8.855\\ 8.855\\ 8.825\\ 8.825\\ 8.8205\\ 8.8209\\ 8.415\\ 8.8415\\ 8.8209\\ 8.8209\\ 8.415\\ 8.845\\ 8.8415\\ 8.845\\$













$\begin{array}{c} 10.823\\ 9.005\\ 9.022\\ 9.003\\ 8.810\\ 8.810\\ 8.8206\\ 8.799\\ 8.442\\ 8.425\\ 8.425\\ 8.425\\ 8.421\\ 8.425\\ 8.421\\ 8.1216\\ 8.137\\ 8.425\\ 7.746\\ 8.421\\ 8.120\\ 1.7335\\ 7.746\\ 7.746\\ 8.1216\\ 7.746\\ 7.746\\ 7.746\\ 7.746\\ 7.746\\ 7.746\\ 7.746\\ 7.746\\ 7.746\\ 7.729\\ 7.7299$



(10.953) (10.953) (10.953) (10.953) (10.953) (10.958) (10.958) (10.958) (10.958) (10.958) (10.958) (10.958) (10.928) (10.81) (














































